Inductive Bio
PrivateLast Round
Grant
Dec 9, 2025
Total Funding Raised
$50.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Inductive Bio operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Grant round in December 2025.
Inductive Bio is a biotechnology company that has developed an AI-powered virtual chemistry lab platform to accelerate small molecule drug discovery and ADMET optimization.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, ML Platforms, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inductive Bio Comparables
Compare Inductive Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TandemAI | 88% | |
| Iktos | 87% | |
| VeriSIM Life | 86% |
For institutional investors. Book with your work email.
Inductive Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 9, 2025 | ||||
| Series A | May 7, 2025 | ||||
| Seed | Dec 13, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Inductive Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A, Seed |
| S32 | Series A |
| AlleyCorp | Seed |
| Character Capital | Series A, Seed |
| Amino Collective | Series A |
| Lux Capital | Series A, Seed |
| Obvious Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 18, 2026
Grew 33% QoQ, from 33 to 44 employees.
- Jul 17, 2026
Grew 19% QoQ, from 32 to 38 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 6, 2026
Inductive Bio, Inc. has launched Indy, an AI assistant that checks assay data, analyzes structure-activity relationships, and handles recurring medicinal chemistry tasks.
- launchesSep 17, 2026
Inductive Bio, Inc. launches Beacon-2 in New York on Sep 17th '26, a system that predicts the efficacious human dose of a small molecule directly from its chemical structure.
For institutional investors. Book with your work email.
Inductive Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Inductive Bio's valuation, stock price, and market status.
Is Inductive Bio a public or private company?
Inductive Bio is a private company.
What is the current stock price of Inductive Bio?
Inductive Bio is a private company, so its shares have no public market price. Caplight tracks Inductive Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inductive Bio worth (valuation)?
Valuation information for Inductive Bio is not publicly available.
Can I buy Inductive Bio stock?
Inductive Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inductive Bio's last funding round?
Inductive Bio's most recent funding round was Grant on December 9, 2025.
Who are the main investors in Inductive Bio?
Key investors in Inductive Bio include Andreessen Horowitz, Lux Capital, Obvious Ventures.
Will Inductive Bio IPO soon?
No public IPO plans have been announced for Inductive Bio.
How can I track Inductive Bio secondary market activity?
Caplight tracks bids, offers, and trades in Inductive Bio's shares on secondary markets.